Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
Who is this study for? Patients with Chronic Obstructive Pulmonary Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects must have a diagnosis of COPD
• at their clinical baseline on the day of imaging
• must be clinically stable in order to participate in the study.
• COPD subjects will be categorized according to the GOLD
• Current/Former SmokerSubjects
• must have a smoking history ≥ 10 pack years
Locations
United States
Virginia
University of Virginia Health System
RECRUITING
Charlottesville
Contact Information
Primary
Sarah Struchen, RN
SS8YM@hscmail.mcc.virginia.edu
4342436074
Backup
Roselove Nunoo-Asare, RT
RNN3B@hscmail.mcc.virginia.edu
4342437363
Time Frame
Start Date: 2018-09-01
Estimated Completion Date: 2020-12-31
Participants
Target number of participants: 30
Treatments
Active_comparator: COPD patients - Xe-133
COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
Experimental: COPD patients - Hyperpolarized Xe-129
COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
Related Therapeutic Areas
Sponsors
Leads: University of Virginia